Core Viewpoint - The company has announced an investment in BoRuiKang Technology (Shanghai) Co., Ltd., focusing on brain-machine interface technology, which is expected to enhance its medical-related project portfolio [1] Group 1: Investment Details - China Merchants China Fund's wholly-owned subsidiary, Shenzhen Tianzheng Investment Co., Ltd., signed a share purchase agreement with BoRuiKang Technology, agreeing to invest 15 million RMB in its E-round financing [1] - The investment was completed on November 7, 2025 [1] Group 2: Company Overview - BoRuiKang Technology, established in November 2011, specializes in the research, development, production, and sales of brain-machine interface systems and related equipment [1] - The company aims to provide comprehensive solutions for innovative research in neuroscience and clinical diagnosis, treatment, and rehabilitation of neurological diseases [1] Group 3: Market Position and Recognition - BoRuiKang Technology has accumulated significant technical reserves and development experience in the brain-machine interface field over the years [1] - Its products are applicable in various research fields, including neuroscience, psychology, human factors engineering, kinesiology, and management, as well as in clinical medicine for diagnosing and treating neurological diseases [1] - The company's research achievements and technical capabilities have been widely recognized by experts in the fields of neural engineering and clinical medicine both domestically and internationally [1] Group 4: Strategic Implications - The investment in BoRuiKang Technology is expected to increase the proportion of medical-related projects within the company's investment portfolio, optimizing its overall investment strategy [1]

Core Viewpoint - China Merchants China Fund (00133.HK) announced that its wholly-owned subsidiary, Shenzhen Tianzheng Investment Co., Ltd., has signed a share purchase agreement with Boryeong Technology (Shanghai) Co., Ltd. to invest 15 million RMB in its E-round financing [1] Company Overview - Boryeong Technology, established in November 2011, focuses on the research, development, production, sales, and technical services of brain-machine interface systems, positioning itself as a high-tech enterprise in mainland China [1] - The company aims to provide comprehensive solutions for innovative research in neuroscience and clinical diagnosis, treatment, and rehabilitation of neurological diseases [1] Technological Expertise - Boryeong Technology has accumulated significant technical reserves and development experience in the brain-machine interface field over the years [1] - Its products are applicable in various research fields, including neuroscience, psychology, human factors engineering, kinesiology, and management science, as well as in clinical medicine for diagnosing, treating, and rehabilitating neurological diseases [1] - The company's research achievements and technical capabilities have gained recognition from experts in the fields of neuroengineering and clinical medicine both domestically and internationally [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED 招商局中國基金有限公司 （於香港註冊成立之有限公司） （股份代號：133） 博睿康技術經過多年在腦機接口領域的悉心耕耘，積累了大量的技術儲備和設備開發經 驗。博睿康技術的產品不僅可廣泛應用於神經科學、心理學、人因工程、運動學、管理學 等科研領域，還可應用於臨床神經疾病診斷、治療與康復工程等臨床醫學領域，其研發成 果與技術實力受到了國內外神經工程與臨床醫學領域專家們的普遍認可。 1 本公司相信，投資博睿康技術將可進一步提高醫療相關項目在本公司投資組合中的比例， 從而使本公司的投資組合更加優化。 代表 招商局中國基金有限公司 董事 投資博睿康技術 招商局中國基金有限公司(「本公司」)宣布，本公司的全資附屬公司 — 深圳市天正投資有 限公司（「天正」）簽訂了日期為2025年10月28日並關於博睿康技術（上海）股份 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 招商局中國基金有限公司 | | | 呈交日期: | 2025年12月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 (B). 承諾發行發行人股份的權證 不適用 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00133 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 152,333,013 | | 0 | | 152,333,013 | | ...

Group 1 - The core point of the article is that China Merchants China Fund (00133) announced its unaudited net asset value per share as of October 31, 2025, which is reported to be 5.609 USD (43.60 HKD) [1]

Group 1 - The core announcement is that China Merchants China Fund (00133) reported an unaudited net asset value per share of $5.609 (HKD 43.60) as of October 31, 2025 [1]

Core Viewpoint - The company announced its unaudited net asset value per share as of October 31, 2025, which is reported to be 5.609 USD (43.60 HKD) [1] Company Summary - The unaudited net asset value per share for China Merchants China Fund (00133.HK) is 5.609 USD [1] - The equivalent value in Hong Kong dollars is 43.60 HKD [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （股份代號：133） 本公司於 2025 年 10 月 31 日之未經審計每股資產淨值為 5.609 美元(43.60 港元)。 香港，2025 年 11 月 14 日 於本公告日期，本公司執行董事為王效釘先生及簡家宜女士；非執行董事為周星先 生、姚望女士、柯世鋒先生及鄒傳先生；及獨立非執行董事為曾華光先生、厲放博 士、宮少林博士、 Michael Charles VITERI 先生及朱琦先生。 CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED 招商局中國基金有限公司 (於香港註冊成立之有限公司) ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 招商局中國基金有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00133 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 152,333,013 | | 0 | | 152,333,013 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 152,333,013 | | 0 | | 152,333,013 | 第 2 ...

Core Viewpoint - The company announced its unaudited net asset value per share as of September 30, 2025, which is reported to be 5.612 USD (43.63 HKD) [1] Summary by Category - **Company Financials** - The unaudited net asset value per share is 5.612 USD (43.63 HKD) as of September 30, 2025 [1]